oxonic acid

Summary

Summary: Antagonist of urate oxidase.

Top Publications

  1. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
  2. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
  3. doi Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
  4. ncbi Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Narikazu Boku
    Shizuoka Cancer Centre, Shizuoka, Japan
    Lancet Oncol 10:1063-9. 2009
  5. pmc Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
    I Mochizuki
    Department of Gastroenterological Surgery, Iwate Central Prefectural Hospital, 1 4 1 Ueda, Morioka, Iwate 020 0066, Japan
    Br J Cancer 106:1268-73. 2012
  6. pmc Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
    E Mochiki
    Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3 39 22, Showa machi, Maebashi, Gunma Cancer Center Hospital, Japan
    Br J Cancer 95:1642-7. 2006
  7. doi Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1
    Toru Aoyama
    Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1 1 2 Nakao, Asahi ku, Yokohama 241 0815, Japan
    Gastric Cancer 14:150-4. 2011
  8. ncbi A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703)
    Yasuhiro Kodera
    Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Gastric Cancer 13:197-203. 2010
  9. doi A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma
    Mariela Blum
    Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, TX, USA
    Future Oncol 7:715-26. 2011
  10. doi Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Kentaro Sudo
    Department of Gastroenterology, Chiba Cancer Center, 666 2 Nitona cho, Chuo Ku, Chiba 260 8617, Japan
    Cancer Chemother Pharmacol 67:249-54. 2011

Detail Information

Publications238 found, 100 shown here

  1. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
    ..Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer...
  2. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
    ....
  3. doi Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
    ..Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage...
  4. ncbi Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Narikazu Boku
    Shizuoka Cancer Centre, Shizuoka, Japan
    Lancet Oncol 10:1063-9. 2009
    ..We aimed to investigate the superiority of irinotecan plus cisplatin and non-inferiority of S-1 compared with fluorouracil, with respect to overall survival, in patients with metastatic gastric cancer...
  5. pmc Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
    I Mochizuki
    Department of Gastroenterological Surgery, Iwate Central Prefectural Hospital, 1 4 1 Ueda, Morioka, Iwate 020 0066, Japan
    Br J Cancer 106:1268-73. 2012
    ..We report the results of a planned safety analysis...
  6. pmc Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
    E Mochiki
    Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3 39 22, Showa machi, Maebashi, Gunma Cancer Center Hospital, Japan
    Br J Cancer 95:1642-7. 2006
    ..The response rate was 54.1%, and the median survival time was 15.5 months. Our phase I/II trial showed that S-1 combined with paclitaxel is effective and well tolerated in patients with advanced gastric cancer...
  7. doi Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1
    Toru Aoyama
    Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1 1 2 Nakao, Asahi ku, Yokohama 241 0815, Japan
    Gastric Cancer 14:150-4. 2011
    ..Some patients experience a recurrence of cancer even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy. The objective of this retrospective study was to clarify the survival and prognosticators in these patients...
  8. ncbi A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703)
    Yasuhiro Kodera
    Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Gastric Cancer 13:197-203. 2010
    ..Moreover, some patients with a preoperative diagnosis of stage II/III turn out to be stage IV after surgical exploration, and a standard postoperative treatment for this population has not been established...
  9. doi A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma
    Mariela Blum
    Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, TX, USA
    Future Oncol 7:715-26. 2011
    ..Based on our review of Phase II and III studies, we conclude that S-1 is a convenient oral fluoropyrimidine that provides safety advantage over intravenous fluorouracil without compromising efficacy against AGC...
  10. doi Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Kentaro Sudo
    Department of Gastroenterology, Chiba Cancer Center, 666 2 Nitona cho, Chuo Ku, Chiba 260 8617, Japan
    Cancer Chemother Pharmacol 67:249-54. 2011
    ..The primary objective of this study was to assess the efficacy and safety of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer...
  11. doi Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin
    Hirofumi Yasui
    Division of GI Oncology, Shizuoka Cancer Center, Sunto gun, Shizuoka, Japan
    Jpn J Clin Oncol 39:315-20. 2009
    ..This retrospective study evaluated the efficacy and safety of monotherapy with S-1 for MCRC after the failure of standard chemotherapy...
  12. ncbi A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer
    H Iwase
    Department of Gastroenterology, Nagoya Medical Center, Japan
    Anticancer Res 25:1297-301. 2005
    ..The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer...
  13. doi A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
    Jae Jin Lee
    Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea
    Cancer Chemother Pharmacol 63:1083-90. 2009
    ..This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer...
  14. pmc Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: phase I trial
    Hiroyuki Harada
    Department of Oral Surgery, Oral Restitution, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, Japan
    J Exp Clin Cancer Res 29:33. 2010
    ..This study was conducted to identify a recommended dose for S-1, used in combination with 40-Gy radiation...
  15. doi Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002)
    Noriya Uedo
    Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka
    Oncology 73:65-71. 2007
    ..To investigate the efficacy and safety of the combination therapy of irinotecan (CPT-11) plus S-1 in patients with advanced gastric cancer at the dose recommended by a previous phase I study...
  16. ncbi Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer
    Daisuke Takahari
    Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Gastric Cancer 13:186-90. 2010
    ..The present study aimed to retrospectively evaluate the efficacy and safety of irinotecan plus cisplatin (IP) therapy after the failure of S-1 in patients with AGC...
  17. ncbi [Late phase II study of S-1 in patients with advanced head and neck cancer]
    Y Inuyama
    Dept. of Otolaryngology, Hokkaido University School of Medicine
    Gan To Kagaku Ryoho 28:1381-90. 2001
    ..Therefore, this event was confirmed to be reversible. Based on these results, we conclude that S-1 is an active agent for the treatment of advanced/recurrent head and neck cancer...
  18. doi Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer
    Wasaburo Koizumi
    Department of Internal Medicine, Kitasato University School of Medicine, 2 1 1 Asamizodai, Sagamihara, Kanagawa 228 8520, Japan
    Int J Cancer 126:162-70. 2010
    ..Our results suggest that these biomarkers are useful for selection of patients with advanced gastric cancer in whom treatment with S-1 alone will yield survival benefit...
  19. ncbi Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases
    Sachio Fushida
    Department of Gastroenterological Surgery, Kanazawa University Hospital, 13 1 Takara machi, Kanazawa 920 8641, Japan
    Anticancer Drugs 20:752-6. 2009
    ..This preoperative DCS therapy was considered feasible and provided a high pathological response rate in gastric cancer patients with para-aortic lymph node metastases...
  20. ncbi A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 66:527-34. 2010
    ..The aim of this study was to investigate the feasibility and efficacy of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer...
  21. doi Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis
    H Ishigami
    Department of Surgical Oncology, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Ann Oncol 21:67-70. 2010
    ..A phase II study to evaluate the efficacy and tolerability of weekly i.v. and i.p. paclitaxel (PTX) combined with S-1 was carried out in gastric cancer patients with peritoneal metastasis...
  22. doi A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 63:313-9. 2009
    ..5% in chemo-naïve patients with pancreatic cancer. This study evaluated the efficacy and toxicity of S-1 in patients with gemcitabine-refractory metastatic pancreatic cancer...
  23. doi Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302)
    Hiroya Takiuchi
    Cancer Chemotherapy Center, Osaka Medical College Hospital, 2 7 Daigakucho, Takatsuki, Osaka, 569 8686 Japan
    Jpn J Clin Oncol 38:176-81. 2008
    ..We evaluated the efficacy of this combination in patients with unresectable or recurrent gastric cancer who had been previously treated with S-1...
  24. pmc Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
    M Kawahara
    Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Osaka, Japan
    Br J Cancer 85:939-43. 2001
    ..1 months. The one-year survival rates of the stage IIIB and IV patients were 30.7% and 47.4%, respectively. S-1 was considered to be an active single agent against NSCLC. Further study of S-1 with other active agents is warranted...
  25. doi S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer
    Min Kyoung Kim
    Division of Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Gyeongju, Republic of Korea
    Jpn J Clin Oncol 39:49-53. 2009
    ..We aimed to evaluate the efficacy and safety of S-1 plus gemcitabine combination chemotherapy as a first-line treatment in patients with locally advanced or metastatic pancreatic cancer...
  26. ncbi A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer
    Yasushi Rino
    Department of Surgery, School of Medicine, Yokohama City University, Japan
    Anticancer Res 26:1455-62. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose (MTD) and the recommended dose of docetaxel with a fixed dose of S-1 in patients with advanced or recurrent gastric cancer...
  27. doi A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Do Youn Oh
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Cancer Chemother Pharmacol 65:527-36. 2010
    ..To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer...
  28. pmc A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
    M Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 96:1650-5. 2007
    ..0 months, respectively. The recommended dose of S-1 therapy with concurrent radiotherapy is 80 mg m(-2) day(-1). A multi-institutional phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway...
  29. doi Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer
    Kentaro Sudo
    Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan
    Int J Radiat Oncol Biol Phys 80:119-25. 2011
    ..The aim of this study was to evaluate safety and efficacy of S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer...
  30. doi A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601)
    Norisuke Nakayama
    Division of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan
    Oncology 75:1-7. 2008
    ..This dose-escalation study of a combination of docetaxel, cisplatin and S-1 investigated the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), recommended dose (RD) and antitumor activity in advanced gastric cancer...
  31. ncbi Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
    Gyeong Won Lee
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea
    Cancer Chemother Pharmacol 64:707-13. 2009
    ..We performed a phase II study of combination chemotherapy with S-1 plus gemcitabine for treating chemo-naïve patients with unresectable pancreatic cancer to evaluate the efficacy and toxicity...
  32. ncbi A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study)
    T Yoshikawa
    Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1 1 2 Nakao, Asahi ku, Yokohama 241 0815, Japan
    Eur J Surg Oncol 36:546-51. 2010
    ..Clinically serosa-positive (T3-4) gastric cancer has a poor prognosis. This phase II trial explored the feasibility and safety of preoperative chemotherapy followed by D2 or D3 gastrectomy in this type of gastric cancer...
  33. doi Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
    Takashi Sasaki
    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Invest New Drugs 30:708-13. 2012
    ..The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC...
  34. doi Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer
    Masato Fujii
    National Institute of Sensory Organs, National Tokyo Medical Center, 2 5 1, Higashigaoka, Meguro ku, Tokyo 152 8902, Japan
    Jpn J Clin Oncol 40:214-21. 2010
    ....
  35. ncbi Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
    Yuji Ueda
    Department of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Gastric Cancer 13:149-54. 2010
    ..A multicenter phase II study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus S-1 in patients with advanced gastric cancer...
  36. ncbi A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer
    Yuriko Takayama
    Department of Digestive Surgery, Nihon University School of Medicine, 30 1 Ohyaguchi kamimachi, Itabashi ku, Tokyo 173 8610, Japan
    Anticancer Res 31:1019-22. 2011
    ..The patient is still alive with no sign of recurrence at 16 months after the disappearance of the original tumor. These results suggest that chemotherapy with S-1 plus CDDP may be effective in early-stage esophageal cancer...
  37. doi Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer
    M Tahara
    Division of Digestive Endoscopy and Gastrointestinal Oncology, East Kashiwa, Chiba, Japan
    Ann Oncol 22:175-80. 2011
    ..we investigated the maximum tolerated dose (MTD) of combination therapy with docetaxel, cisplatin, and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer (HNC)...
  38. doi A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer
    Akihiro Nakajo
    Department of Surgical Oncology and Digestive Surgery, Kagoshima University Graduate School of Medicine, Kagoshima, Japan
    Cancer Chemother Pharmacol 62:1103-9. 2008
    ..The maximum tolerated dose for this regimen had been established previously in a Phase I study performed in Japanese patients...
  39. doi Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer
    Hiroko Hasegawa
    Department of Gastroenterology, National Osaka Medical Center, 2 1 14 Hoenzaka, Chuo Ku, Osaka, Japan
    Chemotherapy 56:436-43. 2010
    ....
  40. ncbi Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
    Y J Choi
    Department of Hemato Oncology, Pusan National University Hospital, Busan, Republic of Korea
    J Laryngol Otol 122:848-53. 2008
    ..This study was performed to assess the efficacy and safety profile of combination treatment with S-1 and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck...
  41. doi Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination
    Yoshiyuki Fujiwara
    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    J Surg Oncol 105:38-42. 2012
    ..This study evaluated the benefits of this combination chemotherapy and subsequent surgery...
  42. doi Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer
    D Takahari
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Cancer Chemother Pharmacol 67:1423-8. 2011
    ..To evaluate the feasibility of S-1 plus cisplatin as adjuvant chemotherapy for stage III gastric cancer after curative resection...
  43. ncbi Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer
    Takashi Oshima
    Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232 0024, Japan
    Oncol Rep 16:361-6. 2006
    ..High concentrations of 5-FU selectively penetrate disseminated peritoneal cells...
  44. ncbi Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
    T Shirasaka
    Institute for Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co, Ltd, Saitama, Japan
    Cancer Res 53:4004-9. 1993
    ..b>Oxonic acid was found to inhibit the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine ..
  45. doi Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
    Benjamin Chuah
    Department of Hematology Oncology, National University Health System, Cancer Sciences Institute of Singapore, National University of Singapore, Singapore
    Cancer Sci 102:478-83. 2011
    ..59; P = 0.002). Grade 3/4 gastrointestinal toxicities were more common in Caucasians than Asians (21%vs 0%). Treatment with S-1 yields no significant difference in 5FU exposure between Caucasians and East Asians...
  46. doi Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1)
    Akira Ono
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto gun, Shizuoka, Japan
    Jpn J Clin Oncol 39:332-5. 2009
    ..5% and 14.2% of the patients, respectively. S-1 was found to show no efficacy and cannot be recommended for second-line chemotherapy against gastric cancer...
  47. doi Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry
    Ke Liu
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 646 Songtao Road, Shanghai 201203, PR China
    J Pharm Biomed Anal 52:550-6. 2010
    ..The validated methods were successfully applied to characterize the pharmacokinetic profiles of FT, 5-FU, CDHP and Oxo following oral administration of 60mg S-1 tablets to patients with solid gastrointestinal tract tumors...
  48. pmc Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas
    Tetsuhiko Shirasaka
    Kitasato Institute for Life Science, Kitasato University, Shirogane, Tokyo, Japan
    Jpn J Clin Oncol 39:2-15. 2009
    ..g. < or =Grade 1 anorexia, fatigue, stomatitis, nausea, vomiting and taste alteration). These two approaches are considered to allow long-lasting therapy with S-1...
  49. ncbi Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice
    Akihiko Suto
    Department of Surgery Yamato Municipal Hospital, 8 3 6 Fukami nishi, Yamato City Kanagawa 242 8602, Japan
    Oncol Rep 15:1517-22. 2006
    ..Down-regulation of the DPD activity of the tumors is also considered to be correlated with the antitumor effect of the treated groups, suggesting its influence on the synergistic effect of the combination therapy...
  50. ncbi Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer
    Ikuo Takahashi
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812 8582, Japan
    Oncol Rep 15:849-54. 2006
    ..The dose limiting toxicity of a combination of S-1 and biweekly DOC was leukopenia and neutropenia. The recommended dose for this combination in phase II study is DOC 35 mg/m2/day...
  51. ncbi [Combination therapy with S-1 and CDDP for head and neck cancer]
    Masato Fujii
    Dept of Otolaryngology, National Tokyo Medical Center, Japan
    Gan To Kagaku Ryoho 33:150-4. 2006
    ..The efficacy and adverse effects of CDDP plus S-1 should be studied in carefully designed phase II/III trials. S-1 will be one of the key drugs for HNSCC in the future...
  52. ncbi Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts
    Ikuo Takahashi
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka, Japan
    Oncology 68:130-7. 2005
    ..Combined therapy with TS-1 and TXT showed enhanced antitumor activity compared with monotherapy of each drug. The outpatient-based treatment of this combination is worth investigating...
  53. ncbi [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer]
    Toshiaki Saeki
    Dept of Clinical Research and Surgery, National Shikoku Cancer Center Hospital
    Gan To Kagaku Ryoho 31:539-47. 2004
    ..Therefore, S-1 may be a new therapeutic agent to prolong the survival period of breast cancer patients due to its high antitumor activity and low toxicity...
  54. ncbi Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts
    Teiji Takechi
    Cancer Research Laboratory, Product Lifecycle Management Department, Taiho Pharmaceutical Co, Ltd, 1 27 Kanda Nishikicho, Chiyoda ku, Tokyo 101 8444, Japan
    Oncol Rep 14:33-9. 2005
    ..These findings suggest that S-1 containing a potent DPD inhibitor may have an antitumor effect on lung tumors, with high basal DPD activity, superior to those of other fluoropyrimidines...
  55. ncbi Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002)
    Hiroya Takiuchi
    Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
    Jpn J Clin Oncol 35:520-5. 2005
    ....
  56. ncbi S-1: a promising new oral fluoropyrimidine derivative
    Muhammad Wasif Saif
    Yale University School of Medicine, Division of Medical Oncology, 333 Cedar Street, FMP 116 New Haven, CT 06520, USA
    Expert Opin Investig Drugs 18:335-48. 2009
    ..The authors review the current literature and provide their expert opinion on the incorporation of S-1 in the treatment of solid malignancies [corrected]...
  57. ncbi Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer
    Shinji Atagi
    National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka, 591 8555, Japan
    J Thorac Oncol 3:1012-7. 2008
    ....
  58. ncbi Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity
    H Fujiwara
    Department of Surgery 1, Iwate Medical University, 020 8505, Morioka, Japan
    Eur J Cancer 39:2387-94. 2003
    ..The superior cytotoxicity of S-1 appears to be attributable to both an increased inhibition of DNA synthesis and an enhanced blockade of RNA function against tumours with a high DPD activity...
  59. doi Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine
    Yoshinori Ito
    Department of Medical Oncology, The Cancer Institute of Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 16:126-31. 2009
    ..We have retrospectively examined the efficacy and safety of S-1 in patients with MBC who had been previously treated with anthracycline, taxane, and capecitabine...
  60. ncbi Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer
    Yoshito Komatsu
    Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Kita ku, Sapporo, Hokkaido 060 8638, Japan
    Adv Ther 27:483-92. 2010
    ..We performed a phase 1/2 study to determine the recommended dose, antitumor activity, and safety of a combination of S-1 and irinotecan in patients with advanced gastric cancer...
  61. doi Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age
    Dae Young Zang
    Department of lnternal Medicine, Hallym University Medical Center and Hallym University College of Medicine, Anyang, South Korea
    Cancer Chemother Pharmacol 63:509-16. 2009
    ..To determine the dose-limiting toxicity (DLT) and activity of combination with docetaxel and S-1 on unresectable gastric cancer...
  62. ncbi Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells
    G Nishimura
    Department of Otorhinolaryngology, Yokohama City University, School of Medicine, 3 9 Fukuura, Kanazawa Ku, 236 0004, Yokohama, Japan
    Cancer Lett 159:1-7. 2000
    ..These results suggest that S-1 will have a higher clinical therapeutic effect against advanced squamous cell carcinoma of the head and neck in humans...
  63. ncbi Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer
    Yasuhide Yamada
    Gastrointestinal Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 8:374-80. 2003
    ..4 : 1. S-1 has a high response rate, of about 40%, in advanced gastric cancer. A phase I study was conducted to assess the maximum tolerated dose and the recommended dose of the combination of irinotecan and S-1...
  64. doi Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer
    Hiroyuki Narahara
    Department of Clinical Oncology, Hiroshima University, Hiroshima, Japan
    Oncology 74:37-41. 2008
    ..A phase II study of weekly paclitaxel combined with S-1, a novel oral fluoropyrimidine, was performed to evaluate the efficacy and tolerability in unresectable or metastatic gastric cancer...
  65. pmc Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
    W Koizumi
    Department of Gastroenterology, School of Medicine, East Hospital, Kitasato University, Kanagawa, Japan
    Br J Cancer 89:2207-12. 2003
    ..8 and 26.3%, respectively, but all were manageable. The RR was 74% (14/19, 95% confidence interval: 54.9-90.6%), and the median survival day was 383. This regimen is considered to be active against AGC with acceptable toxicity...
  66. ncbi Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer
    Kazuhiro Yoshida
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Clin Cancer Res 12:3402-7. 2006
    ..To evaluate the efficacy and toxicity of docetaxel in combination with a novel oral 5-fluorouracil analogue S-1 for patients with advanced or recurrent gastric cancer...
  67. ncbi Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer
    Takeharu Yamanaka
    Cancer Biostatics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, 3 1 1 Notame, Fukuoka, Japan
    Gastric Cancer 10:129-34. 2007
    ..S-1 is an oral fluoropyrimidine that promises better and accessible treatment. This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data...
  68. ncbi Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
    A Goto
    Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 17:968-73. 2006
    ..This phase II study evaluated the efficacy and safety of the oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced or recurrent colorectal cancer...
  69. ncbi A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group
    Toshiaki Saek
    Department of Clinical Research and Surgery, National Shikoku Cancer Center Hospital, Horinouchi 13, Matsuyama 790 0007, Japan
    Breast Cancer 11:194-202. 2004
    ..We investigated its clinical efficacy against metastatic breast cancer...
  70. ncbi A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer
    Hyeong Su Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Gangnam Gu, Seoul 135 710, South Korea
    Int J Colorectal Dis 24:1311-6. 2009
    ..This phase I study was conducted to determine the maximum tolerated dose of S-1 with oxaliplatin and to define its recommended dose for the subsequent phase II study...
  71. pmc EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
    J Van den Brande
    Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat, Edegem, Belgium
    Br J Cancer 88:648-53. 2003
    ..The other toxicities were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations...
  72. ncbi Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan
    Yousuke Nakai
    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo Bunkyo ku, Tokyo 113 8655, Japan
    Jpn J Clin Oncol 40:774-80. 2010
    ..We investigated the impact of S-1 on the prognosis of patients with gemcitabine-refractory pancreatic cancer...
  73. ncbi An early phase II study of S-1 in patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Oncology 68:171-8. 2005
    ..The aim of this study was to evaluate the efficacy and toxicity of S-1 in patients with metastatic pancreatic cancer...
  74. pmc Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    K Nakamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Br J Cancer 94:1575-9. 2006
    ..Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate...
  75. ncbi Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer
    Yasuhiro Tsutani
    Department of Surgery, Saiseikai Hiroshima Hospital, Aki gun, Hiroshima 731 4311, Japan
    Anticancer Res 29:2775-9. 2009
    ..The safety and efficacy of docetaxel plus S-1 combination chemotherapy as a first-line treatment in patients with advanced or recurrent gastric cancer was verified retrospectively...
  76. ncbi Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines
    Yoshiyuki Wada
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Int J Cancer 119:783-91. 2006
    ..These data strongly indicate that a combination chemotherapy of TXT and S-1 is effective against gastric carcinomas and is therefore a good candidate as a standard chemotherapeutic strategy in treating these tumors...
  77. ncbi Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  78. ncbi Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts
    Shin Nakahira
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, E2, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Anticancer Res 28:179-86. 2008
    ..The purpose of this study was to evaluate the relationship between different schedules and the effects of GEM/S-1 combination therapy on pancreatic cancer xenograft models...
  79. ncbi Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination
    Seiji Satoh
    Department of Surgery, Kyoto University Hospital, Kyoto 606 8507, Japan
    Gastric Cancer 9:129-35. 2006
    ..In this study, we analyzed the feasibility and efficacy of NAC with S-1 (TS-1)/cisplatin CDDP in order to design appropriate clinical trials for AGC...
  80. ncbi Just when you thought the fluorouracil debate was over: S-1 and gastric cancer
    David Ilson
    J Clin Oncol 23:6826-8. 2005
  81. ncbi S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa shi, Chiba, 277 8577 Japan
    Cancer Chemother Pharmacol 62:849-55. 2008
    ..5%), anorexia (7.5%) and T-Bil elevation (7.5%). Significant antitumor activity combined with a mild toxicity profile was observed. This monotherapy warrants further evaluation in a randomized study...
  82. ncbi Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study
    Akihito Tsuji
    Department of Clinical Oncology, Kochi Health Science Center, Kochi, Japan
    Anticancer Res 28:1433-8. 2008
    ..In the present study, the efficacy and safety of a combination of S-1 and low-dose twice-weekly cisplatin were investigated...
  83. ncbi A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer
    Naohiro Yonemoto
    Department of Biostatistics, Kyoto University School of Public Health, Yoshida Konoe, Sakyou, Kyoto, Japan
    Jpn J Clin Oncol 37:843-51. 2007
    ..This study examined the effect of five systemic chemotherapy regimens on survival in patients with unresectable biliary tract cancer (BTC) as compared with the best supportive care (BSC)...
  84. ncbi Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma
    Koji Harada
    Department of Therapeutic Regulation for Oral Tumors, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770 8504, Japan
    Oncol Rep 18:1077-83. 2007
    ..Briefly, this 2-week regimen may be a useful concurrent chemo-radiotherapy improving the quality of life (QOL) of patients with OSCC...
  85. ncbi A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma
    Hiroyuki Tsuji
    Department of Otolaryngology, Kanazawa Medical University, Ishikawa, Japan
    Oncology 71:369-73. 2006
    ..Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1...
  86. ncbi A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer
    Y J Kim
    Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Ann Oncol 19:99-103. 2008
    ..Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined. We carried out this study to evaluate the efficacy and toxicity of combination chemotherapy with S-1 and cisplatin in metastatic or relapsed BTC...
  87. ncbi Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy
    Woo Young Kim
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545 8585, Japan
    Cancer Sci 98:1604-8. 2007
    ..However, the dose of S-1 for patients who have undergone total gastrectomy might be diminished to avoid severe adverse events and to continue the treatment for a long period...
  88. ncbi Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
    Hei Cheul Jeung
    Yonsei University College of Medicine, Seodaemun Ku, CPO Box 8044, Seoul, 120 752, Korea
    Oncologist 12:543-54. 2007
    ..We suggest that the pharmacogenomic markers identified in this study may be potential candidates for predicting anemia after S-1 treatment...
  89. doi Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer
    Dae Young Zang
    Department of Internal Medicine, Hallym University Medical Center and Hallym University College of Medicine, Anyang, South Korea
    Cancer Chemother Pharmacol 64:877-83. 2009
    ..To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy on metastatic gastric cancer...
  90. ncbi Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma
    Kuniaki Shirao
    Department of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer 100:2355-61. 2004
    ....
  91. ncbi Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. To decrease the incidence of late onset, severe diarrhea observed in a previous study, a phase I study was conducted to determine the maximum tolerated ..
  92. ncbi Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer
    Kazumasa Fujitani
    Department of Surgery, Osaka National Hospital, Japan
    Oncology 69:414-20. 2005
    ....
  93. pmc Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    K Nakamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan
    Br J Cancer 92:2134-9. 2005
    ..As toxicities were well tolerated and antitumour activities seem to be promising, this combination can be recommended for further phase II studies with APC...
  94. ncbi Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells
    Koji Harada
    Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3 18 15 Kuramoto cho, 770 8504, Japan
    Oral Oncol 40:713-9. 2004
    ....
  95. ncbi The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors
    Patrick Schoffski
    Department of Hematology and Oncology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Anticancer Drugs 15:85-106. 2004
    ..v. and bolus 5-FU and the other oral fluoropyrimidines. Thus, we may finally be seeing the realization of oral treatments for the management of various solid tumors and could be on the brink of a new approach to treatment strategies...
  96. ncbi S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial
    Yukito Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, 3 1 1, Notame, Minami ku Fukuoka, Japan
    Clin Cancer Res 10:7860-4. 2004
    ....
  97. ncbi Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
    C J van Groeningen
    University Hospital Vrije Universiteit, Netherlands Cancer Institute, and NDDO Oncology, Amsterdam, The Netherlands
    J Clin Oncol 18:2772-9. 2000
    ....
  98. pmc Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
    Y Yamada
    Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 89:816-20. 2003
    ..The AUC(0-10 h) of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition...
  99. ncbi Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey
    Hiroki Kawai
    Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Gastric Cancer 6:19-23. 2003
    ..The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution...
  100. ncbi Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
    Fumio Nagashima
    Division of Digestive Endoscopy Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Gastric Cancer 8:6-11. 2005
    ..The aim of this survey was to confirm the safety and efficacy of S-1 for advanced gastric cancer after market release...
  101. pmc Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients
    Emmanuelle Comets
    Department of Pharmacy, Keio University Hospital, Tokyo 160 8582, Japan
    J Pharmacokinet Pharmacodyn 30:257-83. 2003
    ..This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients...

Research Grants60

  1. Molecular Markers of Response to Chemoradiation in Localized Esophageal Cancer
    Jaffer Ajani; Fiscal Year: 2008
    ..Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ..
  2. Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
    Jaffer A Ajani; Fiscal Year: 2010
    ..Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ..
  3. Workshop on Methods in Clinical Cancer Research
    Daniel Von Hoff; Fiscal Year: 2007
    ..Finally, a proven evaluation system is in place to make sure that the Workshop will meet its objectives. ..
  4. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2007
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  5. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2007
    ..abstract_text> ..
  6. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2007
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. [unreadable] [unreadable]..
  7. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2006
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  8. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2006
    ..abstract_text> ..
  9. New Methodology for Indole Alkaloid Syntheses
    Ken S Feldman; Fiscal Year: 2010
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  10. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2004
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  11. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2005
    ..abstract_text> ..
  12. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2005
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  13. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2005
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  14. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2004
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  15. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2004
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  16. Targets to Therapeutics in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
    ..We feel this effort, with new approaches to pancreatic cancer, concentrated in a P01, has a chance to make an impact on the disease. ..
  17. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2008
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  18. New Methodology for Indole Alkaloid Syntheses
    Ken S Feldman; Fiscal Year: 2010
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  19. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2009
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  20. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2009
    ..abstract_text> ..
  21. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel D Von Hoff; Fiscal Year: 2010
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  22. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2009
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  23. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2009
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  24. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2008
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  25. Targets to Therapeutics in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2008
    ..We feel this effort, with new approaches to pancreatic cancer, concentrated in a P01, has a chance to make an impact on the disease. ..
  26. Workshop on Methods in Clinical Cancer Research
    Daniel Von Hoff; Fiscal Year: 2008
    ..Finally, a proven evaluation system is in place to make sure that the Workshop will meet its objectives. ..
  27. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2008
    ..abstract_text> ..
  28. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  29. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2003
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  30. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2003
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  31. RADICAL MEDIATED CYCLIZATION REACTIONS
    Ken Feldman; Fiscal Year: 1992
    ..Successful completion of these syntheses will afford the targets (or analogs) in the most efficient manner to date...
  32. ELLAGITANNIN AND RELATED CHEMISTRY
    Ken Feldman; Fiscal Year: 1999
    ..Finally new strategies for diasteroselective biaryl astropisomer assembly within the context of synthesis efforts directed toward the potent cytotoxic agent diazonamide A will extend current art in this area ..
  33. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2003
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  34. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2002
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  35. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2002
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  36. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2002
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  37. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2001
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  38. ELLAGITANNIN AND RELATED CHEMISTRY
    Ken Feldman; Fiscal Year: 2001
    ..Finally new strategies for diasteroselective biaryl astropisomer assembly within the context of synthesis efforts directed toward the potent cytotoxic agent diazonamide A will extend current art in this area ..
  39. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
    ..abstract_text> ..
  40. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2000
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  41. ELLAGITANNIN AND RELATED CHEMISTRY
    Ken Feldman; Fiscal Year: 2000
    ..Finally new strategies for diasteroselective biaryl astropisomer assembly within the context of synthesis efforts directed toward the potent cytotoxic agent diazonamide A will extend current art in this area ..
  42. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2000
    ..abstract_text> ..
  43. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 1999
    ..abstract_text> ..
  44. ALKYNYLIODONIUM CHEMISTRY IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 1999
    ....
  45. RADICAL MEDIATED CYCLIZATION REACTIONS
    Ken Feldman; Fiscal Year: 1993
    ..Successful completion of these syntheses will afford the targets (or analogs) in the most efficient manner to date...